COMMUNIQUÉS West-GlobeNewswire

-
Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
23/10/2025 -
Instinct Science and Cornell University Hospital for Animals Modernize Veterinary Care with Instinct Treatment Plan
23/10/2025 -
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
23/10/2025 -
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.
23/10/2025 -
Avec Med4Cure, EUROAPI accélère l’innovation pharmaceutique au service de la souveraineté sanitaire
23/10/2025 -
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
23/10/2025 -
eteraflex connects and CliniExperts Announce Global Alliance to Redefine Clinical Research and Regulatory Services Delivery
23/10/2025 -
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
23/10/2025 -
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
23/10/2025 -
Tango Therapeutics Announces $225 Million Financing
23/10/2025 -
Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025
23/10/2025 -
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
23/10/2025 -
Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting
23/10/2025 -
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
23/10/2025 -
Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
23/10/2025 -
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast
23/10/2025 -
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
23/10/2025 -
LifeMD to Report Third Quarter 2025 Financial Results on November 6
23/10/2025 -
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
Pages